跳至內容

富馬地羅昔美

維基百科,自由的百科全書
富馬地羅昔美
臨床資料
商品名英語Drug nomenclatureVumerity
其他名稱ALKS-8700
AHFS/Drugs.comMonograph
MedlinePlusa620002
核准狀況
懷孕分級
給藥途徑口服給藥
ATC碼
法律規範狀態
法律規範
藥物動力學數據
血漿蛋白結合率Monomethyl fumarate (MMF): 27–45%
藥物代謝Esterases, citric acid cycle
代謝產物MMF (active), hydroxyethyl succinimide (HES, inactive), CO2 (inactive)
生物半衰期1 hour
排泄途徑MMF: 60% lung, 15.5% urine (?), 0.9% faeces
HES: 58–63% urine
識別資訊
CAS號1577222-14-0
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C11H13NO6
摩爾質量255.23 g·mol−1
3D模型(JSmol英語JSmol
  • COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O
  • InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+
  • Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N

富馬地羅昔美(英語:Diroximel fumarate,商品名:Vumerity)是一種含氮有機化合物,化學式為C11H13NO6,用於治療復髮型多發性硬化症(MS)[3][5][6]

參考文獻

[編輯]
  1. ^ 1.0 1.1 Vumerity APMDS. Therapeutic Goods Administration (TGA). 4 April 2022 [24 April 2022]. 
  2. ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 21 December 2022 [2 January 2023]. 
  3. ^ 3.0 3.1 Vumerity- diroximel fumarate capsule. DailyMed. [1 February 2021]. (原始內容存檔於5 February 2021). 
  4. ^ Vumerity EPAR. European Medicines Agency. 14 September 2021 [24 November 2021]. (原始內容存檔於25 November 2021). 
  5. ^ Wang Y, Bhargava P. Diroximel fumarate to treat multiple sclerosis. Drugs of Today. July 2020, 56 (7): 431–437. PMID 32648853. S2CID 220471534. doi:10.1358/dot.2020.56.7.3151521. 
  6. ^ Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E. Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. Pharmaceuticals (Basel, Switzerland). October 2020, 13 (10): 306. PMC 7602023可免費查閱. PMID 33066228. doi:10.3390/ph13100306可免費查閱.